Changshan Pharmaceutical announces auditor reappointment, shareholder meeting details

Hebei Changshan Biochemical Pharmaceutical held the fifth meeting of its sixth board of directors on November 14, 2025, which approved the reappointment of Zhongxi Certified Public Accountants (Special General Partnership) as the company’s auditor for 2025. This decision, covering both financial reports and internal control audits for a one-year term, will be submitted for shareholder approval.

The board also resolved to convene the first extraordinary general meeting of shareholders for 2025 on December 1, 2025. This meeting will consider the auditor reappointment and other proposals previously approved by the board, including revisions to the company's articles of association and various management rules. Shareholders can participate in person or via online voting through the Shenzhen Stock Exchange systems.

Zhongxi Certified Public Accountants reported total revenue of CNY 41,845.83 million in 2024, with audit service revenue of CNY 36,575.89 million. The firm serves 40 listed companies and 167 companies, with audit fees totaling CNY 6,027.04 million for listed clients in 2024. The firm carries professional liability insurance with a cumulative compensation limit of CNY 10,000 million.